NKG2A: A Novel Immune Checkpoint Protein for Cancer Treatment

Qiwen Huang

2022

Abstract

Immune checkpoint inhibitor (ICI) drugs have been figured prominently in various of cancer immunotherapy. Immune checkpoint inhibitor monoclonal antibodies (mAbs) targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or its ligand (PD-L1), have achieved unprecedented improvements. Nonetheless, due to some issues such as tumor resistance, genetic heterogeneity, and its intricacy of immune regulatory pathways, immunotherapy remains a major challenge. As a result, it's critical to discover further about immunological checkpoints and the application of their inhibitors in clinical practice. The potential inhibitory CD94/NKG2A receptor has been explored in recently, which involve in the stimulation of both natural killer (NK) and CD8+ T cell immunological activity, as well as predominantly link to immune cell-tumor interaction. However, the specific mechanisms for immune regulation, NKG2Atargetd inhibitors and related clinical trials are still underestimated. Therefore, we'll look at the basic structure and function of CD94/NKG2A, and its immune regulatory mechanisms, as well as the current NKG2Atargeted clinical results in the review.

Paper Citation

in Harvard Style

Huang Q. (2022). NKG2A: A Novel Immune Checkpoint Protein for Cancer Treatment. In Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB, ISBN 978-989-758-595-1, pages 1076-1083. DOI: 10.5220/0011377500003443

in Bibtex Style

@conference{icbeb22,
author={Qiwen Huang},
title={NKG2A: A Novel Immune Checkpoint Protein for Cancer Treatment},
booktitle={Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,},
year={2022},
pages={1076-1083},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0011377500003443},
isbn={978-989-758-595-1},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,
TI - NKG2A: A Novel Immune Checkpoint Protein for Cancer Treatment
SN - 978-989-758-595-1
AU - Huang Q.
PY - 2022
SP - 1076
EP - 1083
DO - 10.5220/0011377500003443